Portopulmonary hypertension (PoPH) is a poorly understood complication of liver disease which affects about 10% of patients with pulmonary hypertension. This case report outlines the difficulties in ...

Background: The prevalence of portopulmonary hypertension (PPHTN) in patients with cirrhosis and refractory ascites is unknown. Its presence may preclude patients from receiving a transjugular ...

Objectives To investigate demographic, clinical characteristics, treatment patterns and healthcare resource utilisation (HCRU) among patients with portopulmonary hypertension (PoPH). Design ...

We report the case of a 54-year-old male patient with a diagnosis of portopulmonary hypertension (POPH) secondary to alcoholic liver cirrhosis (Child-Pugh class C and Model for End-Stage Liver Disease ...

Pulmonary hypertension is a rare, ostensibly incurable, and etiologically diverse disease with an unacceptably high 5-year mortality rate (≈50%), worse than many cancers. Irrespective of pathogenic ...

Only the third description should be labeled portopulmonary hypertension. Chronic HIV infection is related to the development of pulmonary arterial hypertension. [7] ...

It may also be effective in select patients with pulmonary arterial hypertension related to collagen vascular disease, congenital heart disease and portopulmonary hypertension. [27, 28 ...

Patients with pulmonary hypertension associated with congenital heart disease make up an increasing proportion of the total pulmonary hypertension population who bring with them added complexity ...

Idorsia gets FDA approval of Tryvio (aprocitentan) for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that use.

WIDAPLIK™, a newly FDA-approved triple combo pill, promises better blood pressure control for adults, including those starting hypertension treatment for the first time.

High blood pressure affects I in 4 American adults. Find in-depth high blood pressure and hypertension information including its causes, symptoms, and treatments.